Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Akari Therapeutics reported Q2 2026 financial results, highlighting $8.6 million in gross proceeds from financing which bolstered the balance sheet to $7.7 million in cash as of June 30. The net loss for the quarter was $4.8 million, driven by increased R&D spending of $2.1 million as the company advances IND-enabling studies. Operationally, Akari remains on track to initiate a Phase 1 trial for its lead candidate AKTX-101 in mid-2027, with IND-enabling manufacturing and development work progressing. The company also presented preclinical data at ASCO demonstrating synergistic anti-tumor activity with KRAS inhibitors in pancreatic cancer models.
Key figures
- Drug Name
- AKTX-101
- Phase Of Trial
- Phase 1
- Net loss
- $4.8 million
- Ga expenses
- $2.5 million
- Rd expenses
- $2.1 million
- Cash balance
- $7.7 million
- Net proceeds
- $8.0 million
- Private placement gross
- $5.5 million
- Warrant exercises gross
- $3.1 million
- Financing proceeds gross
- $8.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.